Evidence map›Paper›PMID 29374178›Full record

SynthesisScientific reports2018

Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions.

Silva P Kouyoumjian, Hiam Chemaitelly, Laith J Abu-Raddad

2 registry-linked trialsOpen access · goldAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 84 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 14 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03687229 unknown statusnot on this mapstarted 2019, after this paper: background citation

The Effect Of Direct Acting Antiviral Drugs on miRNA-122 And Insulin Resistance In Chronic HCV Patients

Typeobservational_patient_registrySponsorAssiut UniversityRan2019 to 2022Enrolled60ConditionsChronic Hepatitis cArmsA)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR), A)fasting serum glucose, B)Fasting serum insulin
NCT04128358 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?

TypeinterventionalSponsorAssiut UniversityRan2019 to 2021Enrolled180ConditionsIdiopathic Thrombocytopenic PurpuraArmsSerological assay for blood born viral hepatitis, Quantitative microbiological test for HCV
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 14 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Global epidemiology ofSexually transmitted infections · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Silva P KouyoumjianInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.
Hiam ChemaitellyInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.ORCID http://orcid.org/0000-0002-8756-6968
Laith J Abu-RaddadInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. lja2002@qatar-med.cornell.edu.
Weill Cornell Medical College in Qatar · QACornell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Egypt is the most affected nation by hepatitis C virus (HCV) and needs a comprehensive characterization of HCV epidemiology to inform the scale-up of treatment and prevention programs. Systematic reviews, meta-analyses, and meta-regressions were conducted. A total of 25 incidence, 259 prevalence, and 47 genotype studies were identified. Incidence and prevalence levels were high across all populations. Genotype 4 accounted for 94.1% of infections with a relative Shannon Diversity Index of only 14.4%. Pooled mean HCV prevalence was estimated at 11.9% (95% CI = 11.1-12.6%) among the general population, 55.6% (95% CI = 49.4-61.7%) among populations at high risk, 14.3% (95% CI = 10.3-18.8%) among populations at intermediate risk, 56.0% (95% CI = 50.4-61.6%) among populations with liver-related conditions, and 35.0% (95% CI = 27.3-43.1%) among special clinical populations. Mean HCV viremic rate was estimated at 66.7% (95% CI = 61.7-71.5%). Meta-regression indicated 6% lower odds for HCV prevalence for each one-year increment in publication year (AOR = 0.94; 95% CI = 0.92-0.96). HCV prevalence is high with evidence for ongoing transmission mainly through healthcare. Genotype diversity is low with genotype 4 dominance. Two-thirds of antibody-positive Egyptians are chronically infected and need treatment. Clinical populations should be prioritized for screening. Despite the large-scale epidemic, prevalence appears to be declining rapidly consistent with a contracting epidemic.

Indexed as

GenotypeDisease Transmission, InfectiousEgyptHepacivirusHepatitis CHumansIatrogenic DiseaseIncidenceMolecular EpidemiologyPrevalence

Identifiers

PMID29374178
PMCPMC5785953
OpenAlexW2805340896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.